increas forecast driven higher forecast
adjuv set inclus new tumor type estim
increas
forecast azn increas sni
unchang rhhbi expect lower
 data present includ press releas chang
expect nsclc still clear leader sever strong dataset
particularli keytruda chemo combo rhhbi expect
vie runner-up forecast lose less share rhhbi gain less share
pre-asco project upcom dataset could shift landscap
includ os rhhbi
os although believ os result difficult beat
lung share expect vs previous
rhhbi lung share forecast previous comparison
share project remain azn metastat stage unresect
includ adjuv
adjuv opportun grow faster previous expect traction adjuv
set predict consist cowen kol believ adjuv use
approv base pacif data come steadili februari japan
juli chmp posit opinion eu late-juli packag
bolster achiev secondari os endpoint may kol
thought key adopt imfinzi revenu nearli doubl
vs larg due rapid penetr adjuv lung opdivo approv
adjuv melanoma uptak appear strong prepar
eu launch post posit chmp opinion june forecast
adjuv set contribut sale like see shift
toward increas use treatment early-stag cancer
june keytruda approv cervic cancer r/r primari mediastin
b-cell lymphoma pmbcl acceler approv cervic grant base
phase ii continu see earli approv tumor type limit
treatment option opdivo imfinzi phase ii cervic cancer trial read
may juli respect cemiplimab sni phase cervic
cancer estim primari complet januari approv r/r
pmbcl mark second approv keytruda liquid tumor classic hodgkin
lymphoma expect hold share pmbcl pmbcl one sever
liquid tumor current evalu late-stag clinic trial forecast
cervic cancer contribut r/r pmbcl io market
pleas see page report import disclosur
summari chang sale project compani
azn imfinzi durvalumab sale estim increas
reflect increas adjuv lung metastat revenu
lower slightli due decreas market share azn ww pd-
share peg vs previous
opdivo nivolumab forecast increas sinc pre-asco note
primarili due lesser declin nsclc notabl chang includ
increas nsclc increas melanoma off-set slight decreas
tumor type includ decreas gastric told
opdivo sale forecast ww share project
vs previous
keytruda pembrolizumab project also increas sinc pre-
note maintain strong posit metastat lung market
share forecast intact slight increas tumor type
contribut higher project includ addit
cervic cancer r/r pmbcl keytruda revenu project
ww share project vs
previous
bavencio avelumab forecast remain intact
fail hit os treatment metastat nsclc phase javelin
lung trial februari await phase readout rcc
ovarian well javelin lung ww pd-
share project vs previous
rhhbi tecentriq atezolizumab estim decreas
carri primarili lesser growth nsclc sinc pre-asco note
project revenu nsclc decreas rhbbi ww
share project vs previous
sni cemiplimab forecast increas addit
cervic indic sni ww share project remain intact
sale estim compani tumor type total annual sale report red
cowen compani
model base tumor type main focu current metastat adjuv i-o studi melanoma renal cell carcinoma rcc lung cancer gastric cancer bladder cancer head neck cancer tripl neg breast
cancer tnbc classic hodgkin lymphoma chl merkel cell carcinoma mcc hepatocellular carcinoma colorect cancer ovarian cancer cutan squamou cell carcinoma cscc cervic cancer r/r primari
updat model includ estim io therapi adjuv set target earlier stage diseas metastat set advanced/metastatic/relaps refractori case
larg variat potenti io patient rel annual incid tumor type reflect typic stage diagnosi late stage lung gastric earlier stage melanoma
price row us annual cost per patient base keytruda/opdivo monthli wac estim weight averag durat therapi tumor type metastat set page adjuv set page
row inclus country/region differ broken
treatment includ mono combo therapi
cowen compani
reflect modelastrazenecau metastat metastat adjuv lung bladder lung ww sale ww market melanoma gastric lung rcc bladder chl colorect melanoma rcc lung bladder ww sale ww market melanoma lung bladder gastric chl tnbc merkel cell cervic r/r melanoma lung gastric bladder rcc tnbc total ww sale ww market lung rcc merkel cell tnbc merkel cell ww sale ww market lung rcc bladder tnbc rcc bladder tnbc colorect ww sale ww market metastat cscc ww sale ww market metastat adjuv sale row sale ww sale cowen
cowen compani
reflect modellung canceru metastat metastat adjuv azn azn lung ww market rhhbi ww market gastric ww market cell carcinoma rhhbi azn ww market azn bladder ww market neck cancer metastat azn adjuv ww market cancer ww market neg breast cancer ww market cowen
cowen compani
reflect modelcutan squamou cell carcinoma snya none atot ww market hodgkin lymphoma metastat adjuv ww market carcinoma metastat adjuv ww market cell carcinoma metastat adjuv ww market metastat rowm adjuv wwm ovarian ww market azn snya none atot cervic ww market mediastin b-cell lymphoma none atot ww market metastat adjuv sale row sale chg cowen
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
estim market share compani head neck cancer hodgkin lymphoma metastat set
cowen compani
estim market share compani hepatocellular carcinoma merkel cell carcinoma mcc metastat set
cowen compani
estim market share compani cervic r/r primari mediastin b-cell lymphoma pmbcl metastat set
cowen compani
estim market share compani metastat cscc adjuv ovarian cancer
cowen compani
cowen compani
cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale cancershar market patient per sale sale lung cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale cancershar market patient per sale sale ww sale cowen
cowen compani
cancershar adjuv market patient per cancer sale cell carcinoma rcc share adjuv market patient per sale sale lung cancershar adjuv market patient per cancer sale cell carcinoma rcc share adjuv market patient per sale sale ww sale cowen
cowen compani
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale hodgkin lymphoma chl share market patient per sale carcinoma share market patient per sale cancershar market patient per cancer sale colorect mh-crc share market patient per sale cancershar market patient per sale sale cowen
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale hodgkin lymphoma chl share market patient per sale cancershar market patient per cancer sale colorect mh-crc share market patient per sale cancershar market patient per sale sale ww sale cowen
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale sale market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale sale ww sale cowen
cowen compani
cowen compani
market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale hodgkin lymphoma chl share market patient per sale neg breast cancer tnbc share market patient per sale carcinoma share market patient per sale cell carcinoma mcc share market patient per sale colorect cancer mh-crc share market patient per sale cancershar market patient per sale mediastin b-cell lymphoma pmbcl share market patient per sale sale cowen
cowen compani
row market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancershar market patient per neck cancer sale hodgkin lymphoma chl share market patient per neg breast cancer tnbc share market patient per sale carcinoma share market patient per sale cell carcinoma mcc share market patient per sale colorect cancer mh-crc share market patient per sale cancershar market patient per sale mediastin b-cell lymphoma pmbcl share market patient per sale row sale ww sale cowen
market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale neg breast cancer tnbc share market patient per sale sale melanomashar market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
cowen compani
cowen compani
 cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma mcc share market patient per sale sale renal cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma mcc share market patient per sale row sale ww sale cowen
cowen compani
 neg breast cancer tnbc share market patient per sale sale tripl neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale sale market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
colorect mh-crc share market patient per sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale sale colorect mh-crc share market patient per sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
cowen compani
 squamou cell carcinoma cscc share market patient per sale cancershar market patient per sale sale cutan squamou cell carcinoma cscc share market patient per sale cancershar market patient per sale row sale ww sale cowen
cowen compani
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
cancer pt newli annual new case growth growth rate pt lung cancer nsclc pt pt nsclc metastat local advanc diseas diagnosi total potenti lung i-o patient pt therapi pt mono combo therapi melanoma pt newli annual growth rate growth rate pt metastat diagnosi estim total potenti melanoma i-o pt therapi current therapi chemo/target therapi pt mono combo therapi renal cell carcinoma rcc pt newli annual growth rate growth rate pt estim rangetot potenti renal i-o patient pt therapi current therapi new agent futur pt mono combo therapi bladder cancer pt newli annual new case growth pt newli diagnos case advanc total potenti bladder i-o pt therapi pt mono combo therapi gastric cancer pt newli annual new case growth growth rate pt newli diagnos case stage iv total potenti gastric i-o patient pt therapi pt mono combo therapi head neck cancer pt newli annual new case growth pt squamou histolog pt pt advanc local advanc diseas diagnosi total potenti head neck i-o patient pt therapi pt mono combo therapi tripl neg breast cancer tnbc pt newli diagnos flat accord cdc pt metastat diseas breast cancer becom metastat pt metastat diseas pt tnbc metastat breast cancer tripl negativetot potenti tnbc i-o patient pt therapi pt hodgkin lymphoma chl pt newli diagnos flat accord nih pt relaps refractori diseas rate pt relaps refractori diseas refractori diseas respond initi therapi pt therapi pt carcinoma pt newli estim flat annual incid pt advanc diseas diagnos local stage pt unresect diseas diagnos metastat pt therapi diagnos region spread nearbi lymph node pt cell carcinoma mcc pt newli cancer societi estim case per year pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt colorect cancer pt newli newli diagnos accord cdc pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas tumor msi-h pt r/r diseas pt therapi pt squamou cell carcinoma cscc pt newli non-melanoma skin cancer increas year pt advanc region diseas cure surgeri develop region progress advanc inoper minor pt region diseas advanc metastat pt relaps refractori diseas pt therapi pt cancer pt newli estim case incid stabl sinc pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt mediastin b-cell lymphoma pmbcl pt newli diagnos estim nearli case incid stabl pt dlbcl sub-typ estim nhl patient dlbcl pt pt pmbcl sub-typ approxim dlbcl pt pt refractori fail prior refractori untreat relaps pt relaps refractori diseas pt therapi pt total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row cancer pt newli annual growth assum preval tobacco use pt lung cancer nsclc pt pt nsclc metastat initi diagnosi total potenti lung i-o patient pt therapi geograph divers popul hinder penetr pt mono combo therapi melanoma pt newli annual new case growth pt present w/metastasestot potenti melanoma i-o market estimate size us pt therapi pt mono combo therapi renal cell carcinoma rcc pt newli annual growth assum preval tobacco use pt estim rangetot potenti renal i-o patient pt therapi pt mono combo therapi bladder cancer pt newli annual new case growth pt newli diagnos case advanc total potenti bladder i-o pt therapi pt mono combo therapi gastric cancer pt newli annual new case growth pt newli diagnos case stage iv total potenti gastric i-o patient preval emerg market pt therapi yr base penetr develop countri pt mono combo therapi head neck cancer pt newli annual new case growth pt squamou histolog pt pt advanc local advanc diseas diagnosi total potenti head neck i-o patient pt therapi pt i-o given high preval emerg market pt mono combo therapi tripl neg breast cancer tnbc pt newli diagnos flat assum cdc pt metastat diseas breast cancer becom pt metastat diseas pt tnbc metastat breast cancer tripl negativetot potenti tnbc i-o patient pt therapi pt hodgkin lymphoma chl pt newli cancer research estim annual ou incid pt relaps refractori diseas rate pt relaps refractori diseas pt therapi pt carcinoma pt newli estim annual ou incid pt advanc diseas locoregion diseas unresect pt relaps refractori diseas pt therapi pt cell carcinoma mcc pt newli incid pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt colorect cancer pt newli million new case world-wide pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas tumor msi-h pt r/r diseas pt therapi pt squamou cell carcinoma cscc pt newli non-melanoma skin cancer increas year pt advanc region diseas cure surgeri develop region progress advanc inoper minor pt region diseas advanc metastat pt relaps refractori diseas pt therapi pt cancer pt newli estim case incid stabl sinc pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt mediastin b-cell lymphoma pmbcl pt newli diagnos cancer research fund approxim pt dlbcl sub-typ estim nhl patient dlbcl pt pt pmbcl sub-typ approxim dlbcl pt pt refractori fail prior pt relaps refractori diseas pt therapi pt total pt mainten patient w/advanc diseaseestim total pt lung cancer cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
cancer pt newli annual new case growth growth rate pt lung cancer nsclc pt pt non-metastat stage local stage ii region stage early-stag resect without early-stag resect adjuv io potenti lung adjuv io patient pt therapi pt pt newli annual growth rate growth rate pt non-metastat stage present w/metastas project rest i- early-stag resect w/o early-stag resect adjuv io potenti melanoma adjuv io pt therapi current therapi chemo/target therapi pt cell carcinoma rcc pt newli annual growth rate growth rate pt non-metastat stage rcc present local region stage i- early-stag resect w/o early-stag io potenti renal adjuv io patient pt therapi pt cancer pt newli annual new case growth pt non-metastat stage newli case advanc early-stag resect w/o early-stag resect adjuv io potenti bladder adjuv io pt therapi pt cancer pt newli annual new case growth growth rate pt non-metastat stage gastric cancer stage early-stag resect w/o receiv neo/adj doc discret early-stag io potenti gastric adjuv io patient pt therapi pt neg breast cancer tnbc pt newli diagnos flat accord cdc pt pt pt non-metastat stage bc diagnos i- estim stage tabl early-stag resect w/o early-stag io potenti early-stag tnbc adjuv io pt therapi pt cancer pt newli newli diagnos accord cdc pt non-metastat stage local region stage i- diseas early-stag resect w/o i-ii discret stage io-eligbl early-stag io colon resect w/o adj resect w/ possibl adjtot potenti colorect adjuv io patient rectal resect io elig pt therapi pt cancer pt newli newli diagnos accord cdc pt non-metastat stage ovarian cancer diagnos stage i- early-stag resect w/o early-stag io potenti ovarian adjuv io patient pt therapi pt total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row cancer pt newli annual growth assum preval tobacco use pt lung cancer nsclc pt pt non-metastat stage local stage ii region stage nsclc early-stag resect w/o nsclc early-stag io potenti lung adjuv io patient pt therapi geograph divers popul hinder penetr pt pt newli annual new case growth pt present w/metastas project rest i- early-stag resect w/o elig io resect doc discret early-stag io potenti melanoma adjuv io market estimate slightli larger us base kol insight pt therapi pt cell carcinoma rcc pt newli annual growth assum preval tobacco use pt rcc present local region stage i- early-stag resect w/o early-stag io potenti renal adjuv io patient pt therapi pt cancer pt newli annual new case growth pt newli case advanc early-stag resect w/o early-stag io potenti bladder adjuv io pt therapi pt cancer pt newli annual new case growth growth rate pt gastric cancer diagnos stage row early-stag resect w/o early-stag io potenti gastric adjuv io patient pt therapi geograph divers popul hinder penetr pt neg breast cancer tnbc pt newli diagnos flat assum cdc pt breast cancer tripl neg pt pt non-metastat stage bc diagnos i- estim stage tabl early-stag resect w/o early-stag io potenti tnbc adjuv io patient pt therapi geograph divers popul hinder penetr pt cancer pt newli million new case world-wide pt non-metastat stage local region stage i- diseas early-stag resect w/o i-ii discret stage io-eligbl early-stag io colon resect w/o adj resect w/ possibl adjtot potenti colorect adjuv io patient rectal resect io elig pt therapi geograph divers popul hinder penetr pt cancer pt newli new case diagnos ww pt non-metastat stage ovarian cancer diagnos stage i- early-stag resect w/o early-stag io potenti ovarian adjuv io patient pt therapi pt total pt mainten patient early-stag diseaseestim total pt cowen
cowen compani durat therapi respond non respond estim cowen kol feedback
 melanomalungrccbladd ngastrictnbcchlhccmccmh-crccscccervicalr/r durat therapi respond durat non respond averag durat cost per cours ngastrictnbcchlhccmccmh-crccscccervicalr/r durat therapi respond durat non respond averag durat cost per cours cowen
cowen compani durat therapi respond non respond estim cowen kol feedback
 lungmelanomarccbladd gastrictnbccrcovarianpati complet adjuv complet adjuv durat adjuv therapi durat failur averag durat cost per cours gastrictnbccrcovarianpati complet adjuv complet adjuv durat adjuv therapi durat failur averag durat cost per cours cowen
cowen compani
median mo overal mo local advanc phase phase high tmblow tmbhigh tmblow tmbnivo phase nivo phase ii w/yervoy high tmblow tmbnon-squamsquamnivo phase phase phase nivo mg mg mg mg mg mg mg ph i/ii phase pembro pemetrex phase carboplatin-pac nab-pac phase pembro mg/kg mg/kg phase ph ib/ii high monolow monohigh monolow monopembro phase cohort cohort phase cancer non-smal cell lung carcinoma nsclc page osorr month sourc cowen
cowen compani
median mo overal mo phase i- lung ph avelumab vs docetaxel vs docetaxel vs docetaxel w/avastin phase teff-highteff-lowteff-highteff-lowteff-highteff-lowatezo carb pac arm atezo carb pac bev arm arm phase ii atezo chemo brain brain phase ii atezo phase ii atezo phase atezo ib w/avastin /-chemo solid tumor atezo bev arm atezo bev folfox arm atezo carb pac arm arm arm phase atezo w/pt base chemo atezo pac carb compani press releaserhhbyesmo cancer non-smal cell lung carcinoma nsclc page osorr month sourc cowen
cowen compani
yr mo mo nave phase nivo mg/kg phase phase ii nivo mg/kg mg/kg refractori phase nivo mg/kg choic chemo phase nivo mg/kg phase nivo mg/kg mg/kg mg/kg ph adjuv vs resect stage -iv lowbraf mutbraf wtnivo mg/kg mg/kg dose ph i/ii refractori phase refractori phase phase pembro ph ib/ii pembro adjuv phase keytruda ido phase braf melanoma data pool lancet sourc esmo cowen
cowen compani
renal phase iinivo phase phase nivo phase nivo mg/kg mg/kg ph i/ii ph i/ii w/pazopanib cohort pazopanib pazopanib pazopanib ph i/ii w/epacadostat rcc patient epacad prior line treatment epacad prior line treatment epacad ph ib/ii w/lenvatinib rcc patient len pembro treatment histori len pembro treatment histori len pembro ib pk/pd w/axitinib inlyta pembro pembro renal ph ib w/axitinib inlyta avelumab avelumab ph ii w/bev vs ph w/bev vs phase ii avastin phase cancerazndurvalumab phase phase phase phase ii ph i/ii phase phase ii phase phase phase ii phase phase malign page type/companybmysourcemo mo orr cowen
cowen compani
cowen compani
mo yr yr -mpf mo mo hodgkin phase phase ii i/ii w/adcetri phase phase ii hodgkin phase b-cell lymphoma larg b-cell i/iia nivo ibrutinibchron lymphocyt leukemia lymphocyticlymphoma larg b-cell phase phase cell lung cancer phase i/ii nivo phase i/ii nivo phase phase ii canceraznphas malign page cowen
cowen compani
mo yr yr -mpf mo mo phase carcinomamrkpembro phase ib cell carcinomajavelin merkel ph squamou cell carcinoma cscc empower-cscc neck -hpv hpv-monthsphas i/ii monotherapi solid ph ii imfinzi phase nivo liri phase phase phase phase durva treme durva ph durva mono ph pembro mono ph malign page cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
